Skin & AestheticsResearch OnlyS

RU-58841

RU58841

Topical anti-androgen research compound discussed for hair-loss protocols (non-peptide).

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
2
Research grade
S
Community score
146

Trend index

Trackers
2,848

Overview

About RU-58841

Topical anti-androgen research compound discussed for hair-loss protocols (non-peptide).

Category
Skin & Aesthetics
Regulatory status
Research Only
Also known as
RU58841
Self-reports
6

Community

What 6 users report

6 community reports

Positive 100% · Neutral 0% · Negative 0%

Most reported benefits

Energy
6
Mood
6

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
0
25–50
0
50–100
0
100–200
0
200–400
0
400–600
0
600–1000
0
1000–2000
0
2000+
6

Commonly stacked with

Research

Cited research (1)

PubMed

RU 58841, a new specific topical antiandrogen: a candidate for the treatment of androgenetic alopecia

Miyamoto et al., 1997

Source
Wiki study page →

Help

Frequently asked

What do PeptIQ users report about RU-58841?

This page summarizes 6 anonymized self-reports from PeptIQ users who track RU-58841, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for RU-58841?

1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is RU-58841 safe to use?

This wiki does not assess safety or recommend use. RU-58841 is listed as Research Only. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of RU-58841?

Research, primarily in animal models, suggests RU-58841 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of RU-58841?

RU-58841 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified RU-58841 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of RU-58841?

The safety and effectiveness of RU-58841 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on RU-58841?

While there are over 200 published studies on RU-58841, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source